Patient Gateway

RSS Feed

【HER2 · 实例】PFS 达 29 个月，影像学 PD 后延续用药再获长期疾病稳定：瑞康曲妥珠单抗为 HER2 突变 NSCLC 患者带来持久获益_腾讯新闻

Entrectinib-associated perimyocarditis in ROS1-positive NSCLC: a diagnostic and therapeutic dilemma - a case report

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Macrophage state in neoadjuvant and perioperative immunotherapy resistance in resectable NSCLC: a critical appraisal of strategies from CSF1R and CD47–SIRPα to CAR-macrophages

Osimertinib Plus Savolitinib in EGFR-Mutated NSCLC After Disease Progression

ESMO 2026中外圆桌｜董晓荣、Myung‑Ju Ahn、Noemi Reguart、李子明教授：PFS与OS双重获益，SAFFRON研究树立MET异常NSCLC后线治疗标杆_腾讯新闻

Qingjin Desheng Pian attenuates NSCLC progression by suppressing neutrophil extracellular trap formation: involvement of the HMGB1/TLR2/MyD88 axis

EU, Japanese Approval Is Sought for Savolitinib Plus Osimertinib in MET-Driven EGFR-Mutated NSCLC

Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy

Osimertinib-Savolitinib Boosts Survival in MET+ NSCLC